Fosamax lawsuits have been consolidated into a multidistrict litigation for purposes of streamlining discovery and judicial proceedings in the US District Court for the District of New Jersey. Fosamax, Merck’s osteoporosis drug is already facing numerous lawsuits in an MDL in New York for jaw necrosis. However, the new consolidated Fosamax lawsuits are concentrating on femur fractures in those who’ve taken Fosamax for osteoporosis.
Last year, the FDA asked all bisphosphonate drug makers to include an additional warning about atypical femur fractures associated with these drugs, including Fosamax.
The new MDL in New Jersey was requested because the drug’s manufacturer has its headquarters in the Garden State.